<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ciclesonide (nasal): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ciclesonide (nasal): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ciclesonide (nasal): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11569" href="/d/html/11569.html" rel="external">see "Ciclesonide (nasal): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="16758" href="/d/html/16758.html" rel="external">see "Ciclesonide (nasal): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F8002704"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Omnaris;</li>
<li>Zetonna</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869081"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Ciclesonide [DSC];</li>
<li>Omnaris</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F8007837"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Corticosteroid, Nasal</li></ul></div>
<div class="block doa drugH1Div" id="F8002756"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;">
<b>Note:</b> For patients with mucous crusting, rinsing with saline nasal spray before administration can remove mucous crusting and improve nasal coating (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-deShazo.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-deShazo.1'])">Ref</a></span>). If nasal obstruction is so severe that sprays cannot penetrate, consider concomitant use of an intranasal decongestant for up to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32707227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32707227'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed30d02d-dd05-494e-bc5b-0d0387493686">Allergic rhinitis, perennial or seasonal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic rhinitis, perennial or seasonal:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Omnaris: Two sprays (50 mcg/spray) per nostril once daily; maximum: 200 mcg/day</p>
<p style="text-indent:-2em;margin-left:4em;">Zetonna: One spray (37 mcg/spray) per nostril once daily; maximum: 74 mcg/day</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1820e284-41e2-4255-93fb-309e4d01aef5">Nonallergic rhinitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>N</b>
<b>onallergic r</b>
<b>hinitis, </b>
<b>(off label):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Omnaris: 2 sprays (50 mcg/spray) per nostril once daily; maximum: 200 mcg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lieberman.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lieberman.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Zetonna: 1 spray (37 mcg/spray) per nostril once daily; maximum: 74 mcg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lieberman.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lieberman.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992069"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50989387"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doe drugH1Div" id="F8002757"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F8002755"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="16758" href="/d/html/16758.html" rel="external">see "Ciclesonide (nasal): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Product formulations are not interchangeable: Omnaris: One spray delivers 50 mcg; Zetonna: One spray delivers 37 mcg</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5c8123d5-63e1-4fd0-b4d4-fd52eac80de3">Allergic rhinitis, perennial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic rhinitis, p</b>
<b>erennial: </b>Intranasal:</p>
<p style="text-indent:-2em;margin-left:4em;">Omnaris (50 mcg/spray):</p>
<p style="text-indent:-2em;margin-left:6em;">Children 2 to 11 years: Limited data available: 1 or 2 sprays (50 mcg or 100 mcg) <b>per nostril</b> once daily; maximum daily dose: 200 mcg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berger.1','lexi-content-ref-Kim.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berger.1','lexi-content-ref-Kim.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: 2 sprays (100 mcg) <b>per nostril</b> once daily; maximum daily dose: 200 mcg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:4em;">Zetonna (37 mcg/spray): Children ≥12 years and Adolescents: 1 spray (37 mcg) <b>per nostril</b> once daily; maximum daily dose: 74 mcg/<b>day</b></p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="493236ef-6c7e-43e1-b6af-a9ef049ee9c4">Allergic rhinitis, seasonal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic rhinitis, s</b>
<b>easonal:</b> Intranasal:</p>
<p style="text-indent:-2em;margin-left:4em;">Omnaris (50 mcg/spray): Children ≥6 years and Adolescents: 2 sprays (100 mcg) <b>per nostril</b> once daily; maximum daily dose: 200 mcg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:4em;">Zetonna (37 mcg/spray): Children ≥12 years and Adolescents: 1 spray (37 mcg) <b>per nostril</b> once daily; maximum daily dose: 74 mcg/<b>day</b></p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51084769"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; has not been studied.</p></div>
<div class="block dohp drugH1Div" id="F51084770"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children and Adolescents: No dosage adjustment necessary.</p></div>
<div class="block adr drugH1Div" id="F8002721"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (≤11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (3% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (≥2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (≥2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (≥2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (≥2%), strain (≥2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (2% to 7%), nasal discomfort (3% to 6%), pharyngolaryngeal pain (≥3%), bronchitis (≥2%), cough (≥2%; may be dose-responsive), nasal septum disorder (≥2%; may be dose-responsive), oropharyngeal pain (≥2%), sinusitis (≥2%), streptococcal pharyngitis (≥2%), viral upper respiratory tract infection (≥2%), upper respiratory infection (≤2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Angioedema (with angioedema of the lips, angioedema of the oropharynx, and angioedema of the tongue), dizziness, dysgeusia, dyspepsia, leukocytosis, nasal candidiasis, nasal congestion, nasal mucosa ulcer, pharyngeal candidiasis, rhinorrhea, throat irritation, xerostomia</p></div>
<div class="block coi drugH1Div" id="F8002709"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to ciclesonide or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Tuberculosis (TB) infection (latent TB) or disease (active TB) of the respiratory tract.</p></div>
<div class="block war drugH1Div" id="F8002710"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal suppression: When used at excessive doses, may cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">• Delayed wound healing: Avoid nasal corticosteroid use in patients with recent nasal septal ulcers, nasal surgery or nasal trauma until healing has occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox should be avoided; corticosteroids should be used with caution, if at all, in patients with ocular herpes simplex, tuberculosis (TB) infection (latent TB), and/or TB reactivity, or in patients with untreated fungal, viral, or bacterial infections.</p>
<p style="text-indent:-2em;margin-left:4em;">• Local nasal effects: Nasal septal perforation, nasal ulceration, epistaxis, and localized <i>Candida albicans</i> infections of the nose and/or pharynx may occur. Monitor patients periodically for adverse nasal effects.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular disease: Increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with intranasal corticosteroid use; use with caution in patients with a history of increased intraocular pressure, cataracts and/or glaucoma. Consider routine eye exams in chronic users or in patients who report visual changes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Avoid using higher than recommended dosages; suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, or hypercortisolism (Cushing syndrome) may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients, even at recommended doses via intranasal route (monitor growth).</p></div>
<div class="block dosfc drugH1Div" id="F21005931"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;">Omnaris 12.5 g bottles contain 120 actuations. </p>
<p style="text-indent:0em;">Zetonna 6.1 g canisters contain 60 actuations.</p></div>
<div class="block foc drugH1Div" id="F8002800"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol Solution, Nasal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zetonna: 37 mcg/actuation (6.1 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Nasal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Omnaris: 50 mcg/actuation (12.5 g) [contains edetate (edta) sodium (tetrasodium)]</p></div>
<div class="block geq drugH1Div" id="F8002706"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F8002803"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol solution</b> (Zetonna Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">37 mcg/ACT (per gram): $43.02</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Omnaris Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mcg/ACT (per gram): $28.27</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869082"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Nasal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Omnaris: 50 mcg/actuation (7.1 g, 12.5 g) [contains edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mcg/actuation ([DSC])</p></div>
<div class="block adm drugH1Div" id="F8002782"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Intranasal</b> Blow nose to clear nostrils. Insert applicator into nostril, keeping bottle upright, and close off the other nostril. Breathe in through nose. While inhaling, press pump to release spray. Avoid spraying directly onto the nasal septum or into eyes. Discard after the "discard by" date or after labeled number of doses has been used, even if bottle is not completely empty.</p>
<p style="text-indent:-2em;margin-left:2em;">Omnaris: Shake bottle gently before using. Prime pump prior to first use (press 8 times until fine mist appears) or if spray has not been used in 4 consecutive days (press 1 time or until a fine mist appears). Nasal applicator may be removed and rinsed with warm water to clean.</p>
<p style="text-indent:-2em;margin-left:2em;">Zetonna: Use nasal canister with supplied nasal actuator only. Prime pump prior to first use (press 3 times until fine mist appears) or if spray has not been used in 10 consecutive days (press 3 times or until a fine mist appears). If canister and actuator become separated, spray 1 test spray in air before using. Clean outside of nose piece with a clean, dry tissue or cloth weekly; do not wash or put in water.</p></div>
<div class="block admp drugH1Div" id="F52614325"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Intranasal: Blow nose to clear nostrils. Insert applicator into nostril, keeping bottle upright, and close off the other nostril. Breathe in through nose. While inhaling, press pump to release spray. Avoid spraying directly onto the nasal septum or into eyes. Discard after the "discard by" date or after labeled number of doses has been used, even if bottle is not completely empty.</p>
<p style="text-indent:-2em;margin-left:2em;">Omnaris: Shake bottle gently before using. Prime pump prior to first use (press 8 times until fine mist appears) or if spray has not been used in 4 consecutive days (press 1 time or until a fine mist appears). Nasal applicator may be removed and rinsed with warm water to clean.</p>
<p style="text-indent:-2em;margin-left:2em;">Zetonna: Use nasal canister with supplied nasal actuator only. Prime pump prior to first use (press 3 times until fine mist appears) or if spray has not been used in 10 consecutive days (press 3 times or until a fine mist appears). If canister and actuator become separated, spray 1 test spray in air before using. Clean outside of nose piece with a clean, dry tissue or cloth weekly; do not wash or put in water.</p></div>
<div class="block use drugH1Div" id="F8002708"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Seasonal and perennial allergic rhinitis: </b>Management of seasonal and perennial allergic rhinitis.</p></div>
<div class="block off-label drugH1Div" id="F25475334"><span class="drugH1">Use: Off-Label: Adult</span><p>Acute bacterial rhinosinusitis, adjunct to antibiotics (empiric treatment):; Chronic rhinosinusitis:; Nonallergic rhinitis</p></div>
<div class="block cyt drugH1Div" id="F8002734"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F8002735"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: Corticosteroids (Nasal) may diminish the therapeutic effect of Esketamine.  Management: Patients who require a nasal corticosteroid on an esketamine dosing day should administer the nasal corticosteroid at least 1 hour before esketamine.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F8043198"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Outcome data related to the use of ciclesonide in pregnancy have not been located (Alhussien 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Systemic absorption is minimal following nasal inhalation at recommended doses.</p>
<p style="text-indent:0em;margin-top:2em;">Maternal use of intranasal corticosteroids in usual doses is not associated with an increased risk of fetal malformations or preterm birth (ERS/TSANZ [Middleton 2020]). Although use of intranasal ciclesonide is likely acceptable, other agents may be preferred for the treatment of allergic rhinitis during pregnancy (Alhussien 2018; BSACI [Scadding 2017]; ERS/TSANZ [Middleton 2020]).</p></div>
<div class="block brc drugH1Div" id="F13766079"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if sufficient quantities of ciclesonide are absorbed following nasal inhalation to produce detectable amounts in breast milk; however, systemic absorption is minimal at recommended doses.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. However, maternal use of intranasal ciclesonide is considered compatible with breastfeeding (ERS/TSANZ [Middleton 2020]).</p></div>
<div class="block mop drugH1Div" id="F54372352"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor growth in pediatric patients; signs/symptoms of HPA axis suppression/adrenal insufficiency; ocular changes; signs/symptoms of Candida infection (long-term therapy).</p></div>
<div class="block phk drugH1Div" id="F8002743"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: 24-48 hours; further improvement observed over 1-2 weeks in seasonal allergic rhinitis or 5 weeks in perennial allergic rhinitis</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Minimal systemic absorption</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Ciclesonide hydrolyzed to active metabolite, des-ciclesonide via esterases in nasal mucosa and lungs; further metabolism via hepatic CYP3A4 and 2D6</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: &lt;1%</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F11390226"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cyclosistem nasal | Omnaris</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Omnaris</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Ciclex | Cicloson</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Omnaris</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Finorinex | Omnaris</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Finorinex</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Omnaris</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Ciclospray | Osonase</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Omnaris</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Omnaris</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Omnaris</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Omnaris</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Omnaris</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Finorinex</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Omnaris</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Finorinex</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Omnaris</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Omnaris</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Omnaris</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Omnair</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-29164323">
<a name="29164323"></a>Alhussien AH, Alhedaithy RA, Alsaleh SA. Safety of intranasal corticosteroid sprays during pregnancy: an updated review. <i>Eur Arch Otorhinolaryngol</i>. 2018;275(2):325-333. doi: 10.1007/s00405-017-4785-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciclesonide-nasal-drug-information/abstract-text/29164323/pubmed" id="29164323" target="_blank">29164323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berger.1">
<a name="Berger.1"></a>Berger WE, Nayak A, Lanier BQ, et al, “Efficacy and Safety of Once-Daily Ciclesonide Nasal Spray in Children with Allergic Rhinitis,” <i>Pediatr Asthma Allergy Immunol</i>, 2008, 21:73-82.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22438350">
<a name="22438350"></a>Chow AW, Benninger MS, Brook I, et al, “IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,” <i>Clin Infect Dis</i>, 2012, 54(8):e72-112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciclesonide-nasal-drug-information/abstract-text/22438350/pubmed" id="22438350" target="_blank">22438350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-deShazo.1">
<a name="deShazo.1"></a>deShazo RD, Kemp SF. Pharmacotherapy of allergic rhinitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 28, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32707227">
<a name="32707227"></a>Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. <i>J Allergy Clin Immunol.</i> 2020;146(4):721-767. doi:10.1016/j.jaci.2020.07.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciclesonide-nasal-drug-information/abstract-text/32707227/pubmed" id="32707227" target="_blank">32707227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26012297">
<a name="26012297"></a>Guo L, Sun X, Yang J, et al. Clinical study of the combination therapy with intranasal antihistamine and nasal corticosteroids in the treatment of nasal obstruction of persistent non-allergic rhinitis. <i>J Otolaryngol Head Neck Surg.</i> 2015;29(3):243-245, 251.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciclesonide-nasal-drug-information/abstract-text/26012297/pubmed" id="26012297" target="_blank">26012297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kim.1">
<a name="Kim.1"></a>Kim K, Weiswasser M, Nave R, et al, “Safety of Once-Daily Ciclesonide Nasal Spray in Children 2-5 Years of Age with Perennial Allergic Rhinitis,” <i>Pediatr Asthma Allergy Immunol</i>, 2007, 20(4):229-42.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lieberman.1">
<a name="Lieberman.1"></a>Lieberman PL. Chronic nonallergic rhinitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22926173">
<a name="22926173"></a>Marcus CL, Brooks LJ, Draper KA, et al, "Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome," <i>Pediatrics</i>, 2012, 130(3):576-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciclesonide-nasal-drug-information/abstract-text/22926173/pubmed" id="22926173" target="_blank">22926173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31699837">
<a name="31699837"></a>Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force statement on the management of reproduction and pregnancy in women with airways diseases.<i> Eur Respir J</i>. 2020;55(2):1901208. doi: 10.1183/13993003.01208-2019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciclesonide-nasal-drug-information/abstract-text/31699837/pubmed" id="31699837" target="_blank">31699837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16554455">
<a name="16554455"></a>Nave R, Wingertzahn MA, Brookman S, et al, “Safety, Tolerability, and Exposure of Ciclesonide Nasal Spray in Healthy and Asymptomatic Subjects with Seasonal Allergic Rhinitis,” <i>J Clin Pharmacol</i>, 2006, 46 (4):461-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciclesonide-nasal-drug-information/abstract-text/16554455/pubmed" id="16554455" target="_blank">16554455</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Omnaris (ciclesonide) [prescribing information]. Zug, Switzerland: Covis Pharma; May 2019.</div>
</li>
<li>
<div class="reference">
                  Omnaris (ciclesonide) [product monograph]. Oakville, Ontario, Canada: Innomar Strategies Inc; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24654314">
<a name="24654314"></a>Price D, Shah S, Bhatia S, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. <i>J Investig Allergol Clin Immunol</i>. 2013;23(7):495-503.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciclesonide-nasal-drug-information/abstract-text/24654314/pubmed" id="24654314" target="_blank">24654314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25832968">
<a name="25832968"></a>Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. <i>Otolaryngol Head Neck Surg</i>. 2015;152(2 suppl):S1-S39. doi: 10.1177/0194599815572097.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciclesonide-nasal-drug-information/abstract-text/25832968/pubmed" id="25832968" target="_blank">25832968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30239057">
<a name="30239057"></a>Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). <i>Clin Exp Allergy</i>. 2017;47(7):856-889. doi:10.1111/cea.12953<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciclesonide-nasal-drug-information/abstract-text/30239057/pubmed" id="30239057" target="_blank">30239057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29438602">
<a name="29438602"></a>Wise SK, Lin SY, Toskala E, et al. International consensus statement on allergy and rhinology: allergic rhinitis. <i>Int Forum Allergy Rhinol</i>. 2018;8(2):108-352.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciclesonide-nasal-drug-information/abstract-text/29438602/pubmed" id="29438602" target="_blank">29438602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18662584">
<a name="18662584"></a>Zetonna (ciclesonide) [prescribing information]. Zug, Switzerland: Covis Pharma; February 2023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciclesonide-nasal-drug-information/abstract-text/18662584/pubmed" id="18662584" target="_blank">18662584</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Zetonna (ciclesonide) [product monograph]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; January 2012.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9043 Version 186.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
